VaxGen's Claims of Vaccine Efficacy Evanesce in Autumn's Last Light By Richard Jefferys The Bonferroni Blunder On Monday February 24th, 2003, the biotech company VaxGen publicly announced the results of the first ever phase III efficacy trial of an HIV…
Congressional Juggling of Medicare Drug Coverage Leaves Many in the Lurch Surviving the "Donut Hole" With a total of 130 local, regional and national AIDS organizations signing on, TAG included, a letter went out to House and Senate Medicare conferees…
By William E. Arnold, Mark Harrington and A. Cornelius Baker October 2003 The Honorable George W. Bush, President The White House 1600 Pennsylvania Avenue, N.W. Washington, D.C. 20500 Dear Mr. President: As leaders of national, regional and local organizations committed…
Antiretroviral Therapy in Latin America: North of the Southern Cone, a Good Plan Is Hard to Find By Richard Stern Seguro Social or Bust When Agua Buena's Richard Stern writes, below, about a recent trip to the AIDS hospitals and…
By Richard Stern At this point I would like to present some examples of a few "best case" scenarios of access to antiretroviral access in the region. This is by no means a complete list. Agua Buena participated in the…
Latest Licensure Breaks Records for Ho-Hum Reception, yet What Exactly Is There to Be Excited About? By Rob Camp A Co-Formulation Elation? Separated at Birth 3TC Emtriva Earlier this month, the fluoronated 3TC agent, FTC (emtricitabine, Emtriva) received FDA approval…
Take-No-Prisoners Tack on TAG Pipeline Report Snubs Host of Drab Wannabes; Cozies up to Fevered Few "Burned One Time Too Many" Someone's been reading too many Dow Jones publications this summer. For what began as a kind of no-nonsense clinical…
Debating the Relevance of Super SIVs— Plus Dendritic Cells Make Their Big Screen Debut By Richard Jeffreys HIV, in flagrante delicto With part two of our review of the immunological and vaccine offerings at this year’s Retrovirus conference, Richard Jefferys…
Activist Coalition’s Cries Threaten To Scuttle BMS’ Race To Full Approval For Wily Reyataz Getting the labeling wrong On May 13 an FDA advisory committee gave backing to the full approval of Bristol-Myers Squibb’s new protease inhibitor, atazanavir (Reyataz). The…
By Richard Jeffreys The field of immune-based therapies (IBT) offers hope that researchers can develop strategies allowing people with HIV to delay or interrupt antiretroviral therapy, ideally reducing drug resistance problems and side effects due to HAART (highly active antiretroviral…